Health · Medical Research · 17 hrs ago
Small study links semaglutide and tirzepatide to changes in eating habits
A pilot study tracked 38 adults taking semaglutide or tirzepatide for three months.
The participants had obesity, or overweight with weight-related health conditions, and did not have diabetes.
These medicines act on hormone pathways that affect appetite and fullness and are used to support weight management.
Participants lost an average of 7.2 kg over three months and reported changes in cravings, food preferences, meal frequency and feelings of fullness.
The study was observational, with no control group, so it cannot show that the drugs caused the changes.
The findings offer early evidence about eating habits during treatment, but further research is needed to establish what the medicines change.
A pilot study found that adults taking semaglutide or tirzepatide reported changes in eating habits over three months.
The 38 participants lost an average of 7.2 kg during the study.
Reported changes included food preferences, cravings, meal frequency, satiety and hunger between meals.
The researchers said the findings are preliminary and do not establish that the medications caused the changes.
- Who
- Researchers from universities in Italy and the United Kingdom studied 38 adults with obesity or overweight and weight-related health conditions.
- What
- The study examined eating habits and food preferences among people taking semaglutide or tirzepatide.
- When
- Participants were assessed at the start of treatment and three months later. The article was published on 9 November 2026.
- Where
- The research involved institutions in Italy and the United Kingdom.
- Why
- The researchers explored how eating behavior and food preferences changed during treatment with these medications.
This story does not have two clearly opposing sides.
Researchers assessed participants’ eating behaviors and measured clinical and body-related parameters.
Researchers repeated assessments of eating behaviors and measurements; participants had lost an average of 7.2 kg.
- Participants
- 38 adults
- Treatment groups
- 17 received tirzepatide; 21 received semaglutide
- Study duration
- Three months
- Average weight loss
- 7.2 kg
- Study design
- Prospective observational pilot study without randomization or a control group